Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities

被引：37

作者：

Hagan, H

Latka, MH

Campbell, JV

Golub, ET

Garfein, RS

Thomas, DA

Kapadia, F

Strathdee, SA

机构：

[1] Natl Dev Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[2] Nat Res Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[3] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA

[4] Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol, Seattle, WA USA

[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[6] Sch Med, Baltimore, MD USA

[7] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 05期

关键词：

D O I：

10.1086/499951

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment ( e. g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

引用

收藏

页码：669 / 672

页数：4

相关论文

共 22 条

[1] AN INVENTORY FOR MEASURING DEPRESSION [J].

BECK, AT ;

ERBAUGH, J ;

WARD, CH ;

MOCK, J ;

MENDELSOHN, M .

ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&

[2] Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack [J].

Booth, RE ;

Kwiatkowski, CF ;

Chitwood, DD .

DRUG AND ALCOHOL DEPENDENCE, 2000, 58 (03) :219-226

[3] Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C:: a randomized controlled trial [J].

Bruno, S ;

Cammà, C ;

Di Marco, V ;

Rumi, M ;

Vinci, M ;

Camozzi, M ;

Rebucci, C ;

Di Bona, D ;

Colombo, M ;

Craxì, A ;

Mondelli, MU ;

Pinzello, G .

JOURNAL OF HEPATOLOGY, 2004, 41 (03) :474-481

[4] Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? [J].

Edlin, BR ;

Seal, KH ;

Lorvick, J ;

Kral, AH ;

Ciccarone, DH ;

Moore, LD ;

Lo, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :211-214

[5] Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment [J].

Fleming, CA ;

Craven, DE ;

Thornton, D ;

Tumilty, S ;

Nunes, D .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :97-100

[6] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[7] Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory [J].

Golub, ET ;

Latka, M ;

Hagan, H ;

Havens, JR ;

Hudson, SM ;

Kapadia, F ;

Campbell, JV ;

Garfein, RS ;

Thomas, DL ;

Strathdee, SA .

JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (02) :278-290

[8] Neuropsychiatric side effects of HCV therapy and their treatment:: focus on IFNα-induced depression [J].

Hauser, P .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (01) :S37-+

[9] Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts [J].

Kresina, TF ;

Seeff, LB ;

Francis, H .

HEPATOLOGY, 2004, 40 (03) :516-519

[10] Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels [J].

Kronenberger, B ;

Herrmann, E ;

Micol, F ;

von Wagner, M ;

Zeuzem, S .

HEPATOLOGY, 2004, 40 (06) :1442-1449